EmStop has completed the ‘Controlled Arterial Protection to Ultimately Remove Embolic Material’ (CAPTURE-1) early feasibility clinical study which assessed the EmStop embolic protection system. The ...

Trial completion marks an important milestone in the development of the next generation, embolic protection platform MINNEAPOLIS, Nov. 21, 2024 /PRNewswire/ -- Cardiovascular medical device company, ...

The "Embolic Protection Device Market Report, Forecast by Product, Application, Procedure, Material, Usage, End-User, Countries and Company Analysis, 2024-2032" report has been added to ...

Using cerebral embolic protection devices during transcatheter aortic valve implantation (TAVI) procedures does not reduce a patient's risk of experiencing a stroke, according to a large UK clinical ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

TCT 319: Short -Term Clinical Effect of Cerebral Embolic Protection Device Following Transcatheter Aortic-Valve Replacement in Korea Population: The Sentinel Registry (Sentinel) Receive the the latest ...

LONDON — Two years after the large multinational PROTECTED TAVR trial failed to associate a cerebral embolic protection (CEP) device with significant protection from stroke in patients undergoing ...

Medical device company marks trial milestone in the evaluation of its embolic protection device, creates expert advisory board as it navigates growth opportunity TAVR, a transcatheter procedure, ...